| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Minako Yamaoka-Tojo, Taiki Tojo, Naonobu Takahira, Atsuhiko Matsunaga, Naoyoshi Aoyama, Takashi Masuda, Tohru Izum. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease. Cardiovascular diabetology. vol 9. 2010-09-15. PMID:20470376. |
glucagon-like peptide-1 (glp-1) is an incretin hormone that has a wide range of effects on glucose metabolism and cardiovascular function (e.g., improving insulin sensitivity, reduction in appetite, modulation of heart rate, blood pressure and myocardial contractility). |
2010-09-15 |
2023-08-12 |
Not clear |
| A Puddu, D Storace, A Durante, P Odetti, G L Vivian. Glucagon-like peptide-1 counteracts the detrimental effects of Advanced Glycation End-Products in the pancreatic beta cell line HIT-T 15. Biochemical and biophysical research communications. vol 398. issue 3. 2010-09-08. PMID:20599702. |
the glucagon-like peptide-1 (glp-1) is an incretin hormone that increases proinsulin biosynthesis, stimulates insulin secretion, and improves pancreatic beta-cell viability. |
2010-09-08 |
2023-08-12 |
Not clear |
| Christine M Hantouche, Khalil M Bitar, Georges M Nemer, Mounir Y Obeid, Lina N Kadi, Asdghig H Der-Boghossian, Anwar B Bikhaz. Role of glucagon-like peptide-1 analogues on insulin receptor regulation in diabetic rat hearts. Canadian journal of physiology and pharmacology. vol 88. issue 1. 2010-08-31. PMID:20130739. |
treatment with insulin and (or) exendin-4, a glucagon-like peptide-1 (glp-1) analogue, increased tau on the coronary endothelium only. |
2010-08-31 |
2023-08-12 |
rat |
| Burton M Wice, Songyan Wang, Dan L Crimmins, Kelly A Diggs-Andrews, Matthew C Althage, Eric L Ford, Hung Tran, Matthew Ohlendorf, Terry A Griest, Qiuling Wang, Simon J Fisher, Jack H Ladenson, Kenneth S Polonsk. Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism. The Journal of biological chemistry. vol 285. issue 26. 2010-08-24. PMID:20421298. |
the intestinal peptides glp-1 and gip potentiate glucose-mediated insulin release. |
2010-08-24 |
2023-08-12 |
mouse |
| Burton M Wice, Songyan Wang, Dan L Crimmins, Kelly A Diggs-Andrews, Matthew C Althage, Eric L Ford, Hung Tran, Matthew Ohlendorf, Terry A Griest, Qiuling Wang, Simon J Fisher, Jack H Ladenson, Kenneth S Polonsk. Xenin-25 potentiates glucose-dependent insulinotropic polypeptide action via a novel cholinergic relay mechanism. The Journal of biological chemistry. vol 285. issue 26. 2010-08-24. PMID:20421298. |
like humans with t2dm, "gip/dt" animals exhibited a normal insulin secretory response to exogenous glp-1 but a blunted response to gip. |
2010-08-24 |
2023-08-12 |
mouse |
| M T Marino, D Costello, R Baughman, A Boss, J Cassidy, C Damico, S van Marle, A van Vliet, P C Richardso. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clinical pharmacology and therapeutics. vol 88. issue 2. 2010-08-12. PMID:20592721. |
the pharmacokinetics of inhaled glp-1 and the pharmacokinetic-pharmacodynamic (pk-pd) relationship between inhaled glp-1 and insulin were analyzed in two trials, one in healthy normal volunteers and the other in patients with type 2 diabetes. |
2010-08-12 |
2023-08-12 |
human |
| M T Marino, D Costello, R Baughman, A Boss, J Cassidy, C Damico, S van Marle, A van Vliet, P C Richardso. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clinical pharmacology and therapeutics. vol 88. issue 2. 2010-08-12. PMID:20592721. |
inhaled glp-1 appeared to produce plasma levels of glp-1 comparable to those of parenteral administration and sufficient to induce insulin secretion resulting in attenuation of postmeal glucose excursions in subjects with type 2 diabetes. |
2010-08-12 |
2023-08-12 |
human |
| M T Marino, D Costello, R Baughman, A Boss, J Cassidy, C Damico, S van Marle, A van Vliet, P C Richardso. Pharmacokinetics and pharmacodynamics of inhaled GLP-1 (MKC253): proof-of-concept studies in healthy normal volunteers and in patients with type 2 diabetes. Clinical pharmacology and therapeutics. vol 88. issue 2. 2010-08-12. PMID:20592721. |
an e(max) (maximum effect) model described the relationship between glp-1 concentration and insulin release. |
2010-08-12 |
2023-08-12 |
human |
| Marzieh Salehi, Benedict Aulinger, Ronald L Prigeon, David A D'Alessi. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. vol 59. issue 6. 2010-08-10. PMID:20215429. |
effect of endogenous glp-1 on insulin secretion in type 2 diabetes. |
2010-08-10 |
2023-08-12 |
Not clear |
| Marzieh Salehi, Benedict Aulinger, Ronald L Prigeon, David A D'Alessi. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. vol 59. issue 6. 2010-08-10. PMID:20215429. |
the incretins glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) account for up to 60% of postprandial insulin release in healthy people. |
2010-08-10 |
2023-08-12 |
Not clear |
| Marzieh Salehi, Benedict Aulinger, Ronald L Prigeon, David A D'Alessi. Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes. Diabetes. vol 59. issue 6. 2010-08-10. PMID:20215429. |
the primary goal of this study was to determine whether endogenous glp-1 regulates insulin secretion in type 2 diabetes. |
2010-08-10 |
2023-08-12 |
Not clear |
| Samuel Grossma. Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide. Pharmacotherapy. vol 29. issue 12 Pt 2. 2010-08-02. PMID:19947814. |
the incretin effect, mediated by glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), plays an important role in the regulation of insulin secretion in response to oral glucose. |
2010-08-02 |
2023-08-12 |
Not clear |
| Jerry Meec. Pharmacokinetics and pharmacodynamics of liraglutide, a long-acting, potent glucagon-like peptide-1 analog. Pharmacotherapy. vol 29. issue 12 Pt 2. 2010-08-02. PMID:19947815. |
glucagon-like peptide-1 (glp-1) is a gastrointestinal hormone from the incretin family, which stimulates insulin secretion and plays an important role in regulating the enteroinsular axis. |
2010-08-02 |
2023-08-12 |
Not clear |
| E Mannucci, L Pala, M Monami, L Da Vico, G Bardini, I Dicembrini, S Ciani, C Lamanna, N Marchionni, C M Rotell. Glucagon-like peptide-1 response to meals and post-prandial hyperglycemia in Type 2 diabetic patients. Journal of endocrinological investigation. vol 33. issue 3. 2010-07-28. PMID:19783893. |
the impaired response of glucagonlike peptide-1 (glp-1) to meals in diabetic patients can contribute to the pathogenesis of impaired insulin secretion and post-prandial hyperglycemia. |
2010-07-28 |
2023-08-12 |
Not clear |
| Elske T Massolt, Paul M van Haard, Jens F Rehfeld, Eduardus F Posthuma, Eveline van der Veer, Dave H Schweitze. Appetite suppression through smelling of dark chocolate correlates with changes in ghrelin in young women. Regulatory peptides. vol 161. issue 1-3. 2010-07-26. PMID:20102728. |
at the start of the sessions, levels of insulin, glucagon-like peptide-1 (glp-1) and cholecystokinin (cck), but not glucose, correlated with appetite scored on a visual analogue scale (vas). |
2010-07-26 |
2023-08-12 |
Not clear |
| Elske T Massolt, Paul M van Haard, Jens F Rehfeld, Eduardus F Posthuma, Eveline van der Veer, Dave H Schweitze. Appetite suppression through smelling of dark chocolate correlates with changes in ghrelin in young women. Regulatory peptides. vol 161. issue 1-3. 2010-07-26. PMID:20102728. |
chocolate eating and smelling both induced a similar appetite suppression with a disappearance of correlations between vas scores and insulin, glp-1 and cck levels. |
2010-07-26 |
2023-08-12 |
Not clear |
| Yazhou Li, Kara B Duffy, Mary Ann Ottinger, Balmiki Ray, Jason A Bailey, Harold W Holloway, David Tweedie, Tracyann Perry, Mark P Mattson, Dimitrios Kapogiannis, Kumar Sambamurti, Debomoy K Lahiri, Nigel H Grei. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. Journal of Alzheimer's disease : JAD. vol 19. issue 4. 2010-07-22. PMID:20308787. |
hence, the present study characterized the effects of a clinically approved long-acting analogue, exendin-4 (ex-4), of the endogenous insulin releasing incretin, glucagon-like peptide-1 (glp-1), on stress-induced toxicity in neuronal cultures and on amyloid-beta protein (abeta) and tau levels in triple transgenic ad (3xtg-ad) mice with and without streptozocin (stz)-induced diabetes. |
2010-07-22 |
2023-08-12 |
mouse |
| Giuseppe Paoliss. Pathophysiology of diabetes in elderly people. Acta bio-medica : Atenei Parmensis. vol 81 Suppl 1. 2010-07-22. PMID:20518191. |
available anti-diabetic oral drugs include insulin secretagogues (meglitinides and sulfonylureas), biguanides (metformin), alpha-glucosidase inhibitors, thiazolidinediones (tzds) and newly introduced glucagon-like peptide-1 (glp-1) analogues and inhibitors of glp-1 degrading enzyme dipeptidyl peptidase-4 (dpp-4). |
2010-07-22 |
2023-08-12 |
Not clear |
| Edwin T Parlevliet, Judith E de Leeuw van Weenen, Johannes A Romijn, Hanno Pij. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. American journal of physiology. Endocrinology and metabolism. vol 299. issue 2. 2010-07-21. PMID:20530733. |
glp-1 treatment reduces endogenous insulin resistance via activation of central glp-1 receptors in mice fed a high-fat diet. |
2010-07-21 |
2023-08-12 |
mouse |
| Edwin T Parlevliet, Judith E de Leeuw van Weenen, Johannes A Romijn, Hanno Pij. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet. American journal of physiology. Endocrinology and metabolism. vol 299. issue 2. 2010-07-21. PMID:20530733. |
glucagon-like peptide-1 (glp-1) improves insulin sensitivity in humans and rodents. |
2010-07-21 |
2023-08-12 |
mouse |